Ezetimibe/rosuvastatin, sold under the brand name Ridutrin among others, is a combination medication used to treat high cholesterol. In some countries it is sold as a kit or a pack containing two distinct pills.
The combination was approved for medical use in the United States in March 2021.
Medical uses Ezetimibe/rosuvastatin is indicated as an adjunct to diet in people with primary non-familial hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C); and alone or as an adjunct to other LDL-C-lowering therapies in people with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.
Pharmacology Ezetimibe/rosuvastatin combines two lipid-lowering therapies.
Ezetimibe inhibits NPC1L1, the transporter that is responsible for absorption of dietary cholesterol from the intestine. Rosuvastatin inhibits HMG-CoA reductase, an enzyme involved in synthesis of new cholesterol in the liver.
References
External links